Assessment of oral health among patients with multiple sclerosis – A case-control study in polish population
References
- Pérez CA, Cuascut FX, Hutton GJ. Immunopathogenesis, diagnosis, and treatment of multiple sclerosis: A clinical update. Neurol Clin. 2023; 41(1): 87–106.
- Wnuk M, Maluchnik M, Perwieniec J, Podwojcic K, Szelag M, Walkiewicz D, Zakrzewski M, Kulakowska A, Brola W, Rejdak K, et al. Multiple sclerosis incidence and prevalence in Poland: Data from administrative health claims. Mult Scler Relat Disord. 2021; 55: 103162.
- Wender M, Michalowska-Wender G. Clinical trials in relapsing-remitting multiple sclerosis (a new proposal for dealing with basic problems and restrictions). JMS. 2015; 84(2): 104–106.
- Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand. 2011; 124(2): 75–84.
- Bermel RA, Cohen JA. Multiple sclerosis: Advances in understanding pathogenesis and emergence of oral treatment options. Lancet Neurol. 2011; 10(1): 4–5.
- Huang J, Kockum I, Stridh P. Trends in the environmental risks associated with earlier onset in multiple sclerosis. Mult Scler Relat Disord. 2022; 68: 104250.
- Niino M, Miyazaki Y. Role of Vitamin D in multiple sclerosis pathogenesis and therapy. In: Watson RR, Killgore WDS, editors Nutrition and Lifestyle in Neurological Autoimmune Diseases: Multiple Sclerosis. 1st edn. London, United Kingdom: Academic Press; 2017. p. 71–80.
- Filipi M, Jack S. Interferons in the treatment of multiple sclerosis: A clinical efficacy, safety, and tolerability update. Int J MS Care. 2020; 22(4):165–172.
- Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple sclerosis: Mechanisms and immunotherapy. Neuron. 2018; 97(4): 742–768.
- Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol. 2008; 172(1): 146–155.
- Korn T, Mitsdoerffer M, Kuchroo VK. Immunological basis for the development of tissue inflammation and organ-specific autoimmunity in animal models of multiple sclerosis. Results Probl Cell Differ. 2010; 51: 43–74.
- Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci. 2002; 3(4): 291–301.
- Cossu D, Yokoyama K, Hattori N. Bacteria-host interactions in multiple sclerosis. Front Microbiol. 2018; 9: 2966.
- Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, Flemmig TF, Garcia R, Giannobile WV, Graziani F, et al. Periodontitis: Consensus report of workgroup 2 of the 2017 world workshop on the classification of periodontal and peri-implant diseases and conditions. J Clin Periodontol. 2018; 45(Suppl 20): S162–S170.
- Ferreira MC, Dias-Pereira AC, Branco-de-Almeida LS, Martins CC, Paiva SM. Impact of periodontal disease on quality of life: A systematic review. J Periodontal Res. 2017; 52(4): 651–665.
- Alonso R, Fernández-Fernández AM, Pisa D, Carrasco L. Multiple sclerosis and mixed microbial infections. Direct identification of fungi and bacteria in nervous tissue. Neurobiol Dis. 2018; 117: 42–61.
- Teixeira FB, Saito MT, Matheus FC, Prediger RD, Yamada ES, Maia CSF, Lima RR. Periodontitis and Alzheimer’s disease: A possible comorbidity between oral chronic inflammatory condition and neuroinflammation. Front Aging Neurosci. 2017; 9: 327.
- Chen C, Zhu J, Deng X, Yang Z, Lin W, Ma Y, Huang S, Chen L, Liu Y, Zhu F. Severe periodontitis is associated with the serum levels of hypersensitive C reactive protein and lipoprotein-associated phospholipase A2 in the patients of acute ischemic stroke. J Clin Neurosci. 2021; 88: 232–236.
- Sheu JJ, Lin HC. Association between multiple sclerosis and chronic periodontitis: A population-based pilot study. Eur J Neurol. 2013; 20(7): 1053–1059.
- Gustavsen MW, Celius EG, Moen SM, Bjølgerud A, Berg-Hansen P, Nygaard GO, Sandvik L, Lie BA, Harbo HF. No association between multiple sclerosis and periodontitis after adjusting for smoking habits. Eur J Neurol. 2015; 22(3): 588–590.
- Łabuz-Roszak B, Niewiadomska E, Starostka-Tatar A, Kubicka-Bączyk K, Krzystanek E, Arkuszewski M, Tyrpień-Golder K, Rybus-Kalinowska B, Pierzchała B, Pierzchała K. Multiple sclerosis: Oral health, behaviours and limitations of daily oral hygiene – a questionnaire study. Neurol Neurochir Pol. 2019; 53(4): 271–276.
- Busato IM, Ignácio SA, Brancher JA, Moysés ST, Azevedo-Alanis LR. Impact of clinical status and salivary conditions on xerostomia and oral health-related quality of life of adolescents with type 1 diabetes mellitus. Community Dent Oral Epidemiol. 2012; 40(1): 62–69.
- Ying Joanna ND, Thomson WM. Dry mouth – an overview. Singapore Dent J. 2015; 36: 12–17.
- Gurvits GE, Tan A. Burning mouth syndrome. World J Gastroenterol. 2013; 19(5): 665–672.
- Sugiya H. Xerostomia. In: Reference module in biomedical sciences. London, United Kingdom: Elsevier; 2014.
- Lange DE, Plagmann HC, Eenboom A, Promesberger A. Klinische bewertungsverahren zur objektivierung der mundhygiene [Clinical methods for the objective evaluation of oral hygiene]. Dtsch Zahnarztl Z. 1977; 32(1):44–47. German.
- Lange DE. Parodontologie in der täglichen Praxis. Berlin, Chicago, Rio de Janeiro, Tokio: Quintessenz Verlags-GmbH; 1986. p. 461.
- Page RC, Eke PI. Case definitions for use in population-based surveillance of periodontitis. J Periodontol. 2007; 78(7 Suppl): 1387–1399.
- Ainamo J, Barmes D, Beagrie G, Cutress T, Martin J, Sardo-Infirri J. Development of the world health organization (WHO) community periodontal index of treatment needs (CPITN). Int Dent J. 1982; 32(3): 281–291.
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983; 33(11): 1444–1452.
- Thornton-Evans G, Eke P, Wei L, Palmer A, Moeti R, Hutchins S, Borrell LN, Centers for Disease Control and Prevention (CDC). Periodontitis among adults aged ≥30 years – United States, 2009–2010. MMWR Suppl. 2013; 62(3): 129–135.
- Boillot A, El Halabi B, Batty GD, Rangé H, Czernichow S, Bouchard P. Education as a predictor of chronic periodontitis: A systematic review with meta-analysis population-based studies. PLoS One. 2011; 6(7): e21508.
- Cockburn N, Pateman K, Taing MW, Pradhan A, Ford PJ. Managing the oral side-effects of medications used to treat multiple sclerosis. Aust Dent J. 2017; 62(3): 331–336.
- Tsimpiris A, Tsolianos I, Grigoriadis A, Tsimtsiou Z, Goulis DG, Grigoriadis N. Association of chronic periodontitis with multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2023; 77: 104874.
- Santa Eulalia-Troisfontaines E, Martínez-Pérez EM, Miegimolle-Herrero M, Planells-Del Pozo P. Oral health status of a population with multiple sclerosis. Med Oral Patol Oral Cir Bucal. 2012; 17(2): e223–e227.
- Dulamea AO, Boscaiu V, Sava MM. Disability status and dental pathology in multiple sclerosis patients. Mult Scler Relat Disord. 2015; 4(6): 567–571.
- Sexton C, Lalloo R, Stormon N, Pateman K, van der Mei I, Campbell J, Ford P. Oral health and behaviours of people living with multiple sclerosis in Australia. Community Dent Oral Epidemiol. 2019; 47(3): 201–209.
- Covello F, Ruoppolo G, Carissimo C, Zumbo G, Ferrara C, Polimeni A, Vozza I. Multiple sclerosis: Impact on oral hygiene, dysphagia, and quality of life. Int J Environ Res Public Health. 2020; 17(11): 3979.
- Mortazavi H, Akbari M, Sahraian MA, Jahromi AA, Shafiei S. Salivary profile and dental status of patients with multiple sclerosis. Dent Med Probl. 2020; 57(1): 25–29.
- McGrother CW, Dugmore C, Phillips MJ, Raymond NT, Garrick P, Baird WO. Multiple sclerosis, dental caries and fillings: A case-control study. Br Dent J. 1999; 187(5): 261–264.
- Hatipoglu H, Canbaz Kabay S, Gungor Hatipoglu M, Ozden H. Expanded disability status scale-based disability and dental-periodontal conditions in patients with multiple sclerosis. Med Princ Pract. 2016; 25(1): 49–55.
- Baird WO, McGrother C, Abrams KR, Dugmore C, Jackson RJ. Verifiable CPD paper: Factors that influence the dental attendance pattern and maintenance of oral health for people with multiple sclerosis. Br Dent J. 2007;202(1):E4; discussion 40-1.
- Fiske J, Griffiths J, Thompson S. Multiple sclerosis and oral care. Dent Update. 2002; 29(6): 273–283.
- Cockburn N, Pateman K, Taing MW, Pradhan A, Ford PJ. Managing the oral side-effects of medications used to treat multiple sclerosis. Aust Dent J. 2017; 62(3): 331–336.
- Selmi C, Lleo A, Zuin M, Podda M, Rossaro L, Gershwin ME. Interferon alpha and its contribution to autoimmunity. Curr Opin Investig Drugs. 2006; 7(5):451–456.
DOI: https://doi.org/10.2478/ahem-2026-0006 | Journal eISSN: 1732-2693
Language: English
Page range: 60 - 67
Submitted on: Jan 5, 2026
Accepted on: Apr 17, 2026
Published on: Apr 18, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
Related subjects:
© 2026 Sylwia Klewin-Steinböck, Mateusz Tarnowski, Maciej Raczkowski, Radosław Kaźmierski, Marzena Liliana Wyganowska, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.